Mariaelvina Sala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariaelvina Sala has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Daniela Braida
Department of Pharmacology, Chemotherapy and medical Toxicology, University of Milan, Faculty of Mathematical, Physical and Natural Sciences, Via Vanvitelli 32, Italy
2 shared publications- Daniela Braida
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
1 shared publication Morena Pozzi
1 shared publicationRamona Cavallini
1 shared publication
Latest Publications
- 1 August 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 136 (8) , 1089-1092
Role of the endocannabinoid system in MDMA intracerebral self‐administration in rats
I.c.v. self‐administration of MDMA (0.01–2 μg per infusion), alone and in combination with CP 55,940 (0.4 μg infusion−1), was studied on an operant responding procedure. On the basis of individual preference for one of two levers, developed during training, rats were allowed to self‐administer vehicle from the preferred lever and MDMA from the other. Pressings on the MDMA associated‐lever, except for the maximal unit dose, progressively increased. The combination of CP 55,940 with MDMA (1 μg infusion−1) reduced the number of drug‐associated lever pressings compared to the single drugs. Pre‐treatment with SR 141716A (0.5 mg kg−1 i.p.), 15 min before each daily session, significantly increased MDMA self‐administration. These findings suggest that MDMA self‐administration is under endogenous tonic control by the endocannabinoid system.British Journal of Pharmacology (2002) 136, 1089–1092. doi:10.1038/sj.bjp.0704825
- 1 August 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 136 (8) , 1089-1092
Role of the endocannabinoid system in MDMA intracerebral self‐administration in rats
I.c.v. self‐administration of MDMA (0.01–2 μg per infusion), alone and in combination with CP 55,940 (0.4 μg infusion−1), was studied on an operant responding procedure. On the basis of individual preference for one of two levers, developed during training, rats were allowed to self‐administer vehicle from the preferred lever and MDMA from the other. Pressings on the MDMA associated‐lever, except for the maximal unit dose, progressively increased. The combination of CP 55,940 with MDMA (1 μg infusion−1) reduced the number of drug‐associated lever pressings compared to the single drugs. Pre‐treatment with SR 141716A (0.5 mg kg−1 i.p.), 15 min before each daily session, significantly increased MDMA self‐administration. These findings suggest that MDMA self‐administration is under endogenous tonic control by the endocannabinoid system.British Journal of Pharmacology (2002) 136, 1089–1092. doi:10.1038/sj.bjp.0704825
- 1 January 2002
- Published by American Psychological Association (APA) in Behavioral Neuroscience
- Vol. 116 (2) , 298-304
3,4 Methylenedioxymethamphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats.
The recreational use of 3,4 methylenedioxymethamphetamine (ecstasy) in humans has been associated with memory impairment. The present study examined whether ecstasy impairs short- and long-term working memory and the pattern of arm entries in rats tested in the 8-arm radial maze with a 2-hr delay. After completing the training session, the rats were given a single dose of ecstasy (1, 2, or 3 mg/kg ip) 20 min before the test. The highest dose slightly affected short-term working memory. Under conditions of delay, there was a progressive deficit in long-term working memory, starting from 1 mg/kg. Under both test conditions, 2 and 3 mg/kg flattened the pattern of arm entry. None of the doses caused hyperlocomotion or stereotypy in the radial maze. These findings suggest that acute ecstasy mainly affects the long-term components of working memory and disrupts the pattern of arm entry in a way similar to serotonergic agents.
- 1 January 2002
- Published by American Psychological Association (APA) in Behavioral Neuroscience
- Vol. 116 (2) , 298-304
3,4 Methylenedioxymethamphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats.
The recreational use of 3,4 methylenedioxymethamphetamine (ecstasy) in humans has been associated with memory impairment. The present study examined whether ecstasy impairs short- and long-term working memory and the pattern of arm entries in rats tested in the 8-arm radial maze with a 2-hr delay. After completing the training session, the rats were given a single dose of ecstasy (1, 2, or 3 mg/kg ip) 20 min before the test. The highest dose slightly affected short-term working memory. Under conditions of delay, there was a progressive deficit in long-term working memory, starting from 1 mg/kg. Under both test conditions, 2 and 3 mg/kg flattened the pattern of arm entry. None of the doses caused hyperlocomotion or stereotypy in the radial maze. These findings suggest that acute ecstasy mainly affects the long-term components of working memory and disrupts the pattern of arm entry in a way similar to serotonergic agents.
- Open Access
- 1 December 2001
- Published by Wiley in CNS Drug Reviews
- Vol. 7 (4) , 369-386
Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies
Eptastigmine (heptyl‐physostigmine tartrate) is a carbamate derivative of physostigmine in which the carbamoylmethyl group in position 5 of the side chain has been substituted with a carbamoylheptyl group.In vitroandex vivoresults suggest that eptastigmine has a long‐lasting reversible brain cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) inhibitory effect. When administeredin vivoto rodents by various routes, eptastigmine inhibits cerebral acetylcholinesterases (AChE) and increases acetylcholine (Ach) brain levels by 2500–3000%, depending on the dose. This effect leads to an improvement in the cerebral blood flow in the ischemic brain, excitatory and inhibitory effects on the gastrointestinal tract and to a protection from acute soman and diisopropylflu‐orophosphate intoxication.Eptastigmine, by either acute or chronic administration, has been found to have memory enhancing effects in different species of normal, aged and lesioned animals. It also restored to normal the age‐related increase of EEG power without affecting spontaneous motor activity.Clinical investigations on more than 1500 patients with Alzheimer's disease demonstrated that eptastigmine significantly improved cognitive performance (as assessed by the cognitive subscale of the Alzheimer's Disease Assessment Scale) as compared with placebo. This improvement was most evident in patients with more severe cognitive impairment at the baseline. The relationship between patient performance and average steady‐state AChE inhibition was described by an inverted U‐shaped dose‐response curve.Pharmacokinetic studies have revealed that after oral administration eptastigmine is rapidly distributed to the tissues and readily enters the CNS, where it can be expected to inhibit AChE for a prolonged period.Eptastigmine is generally well tolerated and the majority of adverse events (cholinergic) were mild to moderate in intensity. However, the adverse hematologic (granulocytopenia) effects reported in two studies have resulted in the suspension of further clinical trials.
- 1 December 2001
- Published by Wiley in CNS Drug Reviews
- Vol. 7 (4) , 369-386
Open AccessEptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies
Eptastigmine (heptyl‐physostigmine tartrate) is a carbamate derivative of physostigmine in which the carbamoylmethyl group in position 5 of the side chain has been substituted with a carbamoylheptyl group.In vitroandex vivoresults suggest that eptastigmine has a long‐lasting reversible brain cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) inhibitory effect. When administeredin vivoto rodents by various routes, eptastigmine inhibits cerebral acetylcholinesterases (AChE) and increases acetylcholine (Ach) brain levels by 2500–3000%, depending on the dose. This effect leads to an improvement in the cerebral blood flow in the ischemic brain, excitatory and inhibitory effects on the gastrointestinal tract and to a protection from acute soman and diisopropylflu‐orophosphate intoxication.Eptastigmine, by either acute or chronic administration, has been found to have memory enhancing effects in different species of normal, aged and lesioned animals. It also restored to normal the age‐related increase of EEG power without affecting spontaneous motor activity.Clinical investigations on more than 1500 patients with Alzheimer's disease demonstrated that eptastigmine significantly improved cognitive performance (as assessed by the cognitive subscale of the Alzheimer's Disease Assessment Scale) as compared with placebo. This improvement was most evident in patients with more severe cognitive impairment at the baseline. The relationship between patient performance and average steady‐state AChE inhibition was described by an inverted U‐shaped dose‐response curve.Pharmacokinetic studies have revealed that after oral administration eptastigmine is rapidly distributed to the tissues and readily enters the CNS, where it can be expected to inhibit AChE for a prolonged period.Eptastigmine is generally well tolerated and the majority of adverse events (cholinergic) were mild to moderate in intensity. However, the adverse hematologic (granulocytopenia) effects reported in two studies have resulted in the suspension of further clinical trials.